- Conditions
- Gonadal Dysgenesis, Turner's Syndrome
- Interventions
- Growth Hormone (Humatrope)
- Drug
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- Female only
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1987 – 2003
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Breast Cancer
- Interventions
- PF-07248144, Fulvestrant, Everolimus, Exemestane
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 102
- States / cities
- Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 85 more
- Conditions
- Healthy Volunteers
- Interventions
- Oral Contraceptive (Ortho Tri-Cyclen or its generic equivalent), CC-99677
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years to 48 Years · Female only
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 3
- States / cities
- Miami, Florida • Marlton, New Jersey • Austin, Texas
- Conditions
- Metastatic Breast Cancer
- Interventions
- Ribociclib + Letrozole OR Fulvestrant, Palbociclib + Letrozole OR Fulvestrant, Paclitaxel +/- Tislelizumab
- Drug
- Lead sponsor
- SOLTI Breast Cancer Research Group
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 26
- States / cities
- Clearwater, Florida • Coral Gables, Florida • Hollywood, Florida + 22 more
- Conditions
- Estrogen Levels Among Breast Cancer Patients
- Interventions
- Estradiol
- Drug
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Locally Advanced (Inoperable) or Metastatic Breast Cancer
- Interventions
- Capivasertib, Fulvestrant, Palbociclib, Ribociclib, Abemaciclib
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 893 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 40
- States / cities
- Tucson, Arizona • Fountain Valley, California • Glendale, California + 35 more
- Conditions
- Menopause, Aging
- Interventions
- Elagolix Oral Tablet, Estradiol patch, cellulose placebo, placebo patch
- Drug · Other
- Lead sponsor
- Penn State University
- Other
- Eligibility
- 42 Years to 64 Years · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- University Park, Pennsylvania
- Conditions
- Uterine Fibroids, Heavy Menstrual Bleeding
- Interventions
- Elagolix, Placebo for Estradiol/Norethindrone Acetate, Estradiol/Norethindrone Acetate, Placebo for Elagolix
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 51 Years · Female only
- Enrollment
- 413 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 92
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Costa Mesa, California + 79 more
- Conditions
- Healthy
- Interventions
- Fulvestrant
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 50 Years to 80 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Breast Cancer
- Interventions
- Letrozole, Placebo
- Drug · Other
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 35 Years to 120 Years · Female only
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2013
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • Philadelphia, Pennsylvania • Houston, Texas
- Conditions
- Advanced Solid Tumor, Advanced Breast Cancer, Advanced Ovarian Cancer
- Interventions
- BMS-986500, Palbociclib, Fulvestrant
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 234 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Fullerton, California • Greenbrae, California + 11 more
- Conditions
- Pharmacokinetics
- Interventions
- Norethindrone/Ethinyl Estradiol, Colchicine, Placebo (for Colchicine)
- Drug
- Lead sponsor
- Mutual Pharmaceutical Company, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Fargo, North Dakota
- Conditions
- Breast Cancer, Cancer of the Breast, Neoplasms, Breast
- Interventions
- Estrace, Anastrozole
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • Voorhees Township, New Jersey • Philadelphia, Pennsylvania
- Conditions
- Advanced Breast Cancer
- Interventions
- AZD2171, Fulvestrant
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years · Female only
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2016
- U.S. locations
- 6
- States / cities
- Burbank, California • Los Angeles, California • Palm Springs, California + 3 more
- Conditions
- Healthy Female Participants
- Interventions
- Zibotentan, EE/LNG
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 35 Years to 75 Years · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Brooklyn, Maryland
- Conditions
- Healthy Volunteers
- Interventions
- Obicetrapib, Obicetrapib + Drospirenone / Ethinyl Estradiol (COC), Drospirenone / Ethinyl Estradiol (COC)
- Drug
- Lead sponsor
- NewAmsterdam Pharma
- Industry
- Eligibility
- 18 Years to 35 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Advanced Breast Cancer
- Interventions
- Saruparib (AZD5305), Camizestrant, Abemaciclib, Ribociclib, Palbociclib, Fulvestrant, Letrozole, Anastrozole, Exemestane
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 788 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 57
- States / cities
- Gilbert, Arizona • Fountain Valley, California • Glendale, California + 49 more
- Conditions
- Cancer of the Prostate
- Interventions
- BHR-200 (0.36% transdermal 17β-estradiol gel), Placebo
- Drug
- Lead sponsor
- BHR Pharma, LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 12
- States / cities
- Tucson, Arizona • Aventura, Florida • Daytona Beach, Florida + 9 more
- Conditions
- Postmenopause, Aging
- Interventions
- Estradiol infusion, Progesterone infusion
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 45 Years to 80 Years · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2000 – 2015
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Endometriosis
- Interventions
- 40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate
- Drug
- Lead sponsor
- Main Line Health
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Wynnewood, Pennsylvania
- Conditions
- Menopause, Irritable Mood
- Interventions
- Estradiol Patch, 0.1 mg/24 Hours Weekly Transdermal Film, Extended Release, Placebo, Progesterone 200 mg
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 45 Years to 59 Years · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Menopause
- Interventions
- esterified estrogens 0.625 mg and methyltestosterone 1.25 mg
- Drug
- Lead sponsor
- Solvay Pharmaceuticals
- Industry
- Eligibility
- 30 Years to 65 Years · Female only
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 77
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Montgomery, Alabama + 74 more
- Conditions
- Prostate Cancer
- Interventions
- Degarelix, Doxorubicin, Ketoconazole, Docetaxel, Estramustine
- Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- HIV Infections
- Interventions
- Ortho Tri-Cyclen LO, Ortho Cyclen, Ortho Cyclen + Efavirenz
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2007
- U.S. locations
- 2
- States / cities
- San Diego, California • Tacoma, Washington